A recent phase 3 trial demonstrated that a personalized approach using ibrutinib-venetoclax therapy, based on measurable residual disease, improves progression-free survival and overall survival in patients...
A new retrospective study examines treatment trends among men with limited life expectancy diagnosed with prostate cancer in the Veterans Affairs health system from 2000 to 2019. Researchers explored...
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
In a prospective randomized controlled trial, researchers evaluated the effectiveness of virtual reality as a nonpharmacologic therapy for pain in hospitalized patients with cancer.
In a population-based, cross-sectional study, researchers examined US women aged 20 to 49 years who were diagnosed with primary invasive breast cancer from 2000 through 2019.
In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...
